Hdacs And Dna Methyl Transferases Were Together Administered

MGCD0103 is a well tolerated isotype specific inhibitor. The inhibitors to HDACs have a potential to rectify the gene expression changes. Depending on the types of cancers they can show effective results as single agents or in combination with other inhibitors. For example in lymphoma cases they can inhibit the tumor growth alone but during myeloid leukemias a combination of these inhibitors has to be administered along with DNMT inhibitors. MGCD0103 is one such inhibitor of HDACs which stimulates the death of cells and the process of autophagy. It effects the functioning of microtubules when administered along with proteasomal inhibitors. Various preclinical studies have shown that it is a promising anti- cancerous agent [1].



MGCD0103 INDUCES APOPTOSIS IN LEUKEMIA CELLS



A collection of monoclonal B lymphocytes is stimulated within the bone marrow or peripheral blood during the chronic cases of lymphocytic leukemia. These tumor cells have an abnormally long life as the process of apoptosis is inhibited within them. Many chemotherapeutic agents have failed in attaining success against them. HDAC inhibitors have emerged as promising candidates against such kinds of cancers. MGCD0103 is one such inhibitor which shows isoform specific reactions. This benzamide derivate target the HDACs belonging to classes I, II, III and XI. Its action was compared with Vorinostat and Entinostat. The performance of MGCD0103 was found to be far better than these two inhibitors with regard to antiproliferative effect or stimulation of apoptosis. The toxic effects were also found to be low with this inhibitor. After phase I clinical trials it was found that this inhibitor could be safely administered in cases of lymphoma and leukemia. After phase II studies within CLL cases, it was found that it was more effective in those patients who did not receive any previous treatment. It also showed significant results when administered in combination with other agents [2].



DNMTs AND HDAC INHIBITORS TOGETHER FIGHT AGAINST LUNG CANCER



When HDACs and DNA methyl transferases were together administered the survival levels of SCLC was dropped down drastically. A combination of decitabine (DNMT inhibitor) and MGCD0103 (HDAC inhibitors) were administered to SCLC cell lines. Out of total 9 cell lines chose 5 of them lost their viability. The underlying reason behind such inhibition is considered to be non-epigenetic mechanism. These results also suggest that the synergistic activity of these two inhibitors stimulates the damage to DNA [3].



MGCD0103 INHIBITS THE MICROTUBULE ACTIVITY



Apart from inhibiting the action of histone deacetylases they have also acted as angiogenesis inhibitors. It is generally noted that the cytotoxic effects shown by the HDACs are majorly because of their potential to inhibit the action of HDACs belonging to class I. Various tumors within the body have shown a higher levels of HDAC enzymes belonging to class I. The HDACs 1 and 2 which belong to class I primarily regulate the process of proliferation. The process of apoptosis is regulated by HDAC2. MGCD0103 was compared with SAHA to study the effects on the cell cycle. It showed specific cytotoxic effects on tumor cells only and this action was similar to that of SAHA. The process of mitosis was delayed showing a failure within this process of cell division. It also stimulates the mitotic slippage during the subsequent stages. During the initial phases it did not stimulate the induction of p21. After a prolonged treatment for 12 hours it stimulated p21 and arrested the cell cycle at the gap1 phase. The microtubules get destabilized under the action of this inhibitor. This disturbance is seen both during the interphase stage and during the process of mitosis.





CONCLUSION



In summary MGCD0103 adopts a unique mechanism of stimulating cytotoxicity. It disturbs the mitosis by hampering microtubules.